Home › Targets › PDGFRA
Radioligand therapy target profile

PDGFRA: IHC Expression in Cancer and Radioligand Target Profile

platelet derived growth factor receptor alpha · Ensembl ENSG00000134853 · Data updated 2026-11-01

PDGFRA, platelet derived growth factor receptor alpha, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, PDGFRA staining is highest in glioma (33% of samples positive), melanoma (10% of samples positive) and ovarian cancer (8% of samples positive). Published literature reports that PDGFRA internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: FDA-approved drug (any modality).

Is PDGFRA the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze PDGFRA free
LocalizationCell-Surface
Top cancer (IHC)Glioma
InternalizationYes
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.91

Is PDGFRA a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

PDGFRA IHC staining by cancer type

Protein expression of PDGFRA across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Glioma0.17Low33%
Melanoma0.07Low10%
Ovarian Cancer0.06Low8%
Testicular Cancer0.05Low14%
Bladder Cancer0.03Low9%

Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, lymphoma, breast cancer, kidney cancer, thyroid cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, endometrial cancer, liver cancer.

Is PDGFRA internalized?

Yes. We discovered that PDGFRA can be targeted to autophagic degradation by binding the autophagy cargo receptor SQSTM1.

Sources: PMID 38634484 · PMID 38113891 · PMID 38004483 · PMID 23127761 · PMID 18701889. AI-extracted from abstracts, so verify before citing.

PDGFRA clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for PDGFRA yet. Search ClinicalTrials.gov for PDGFRA trials.

PDGFRA normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PDGFRA in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

PDGFRA gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -0.20 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related glioma radioligand targets

EGFR · HER3 (ERBB3) · c-MET (MET) · ITGAV · B7-H3 (CD276) · SSTR2 · STEAP2 · TMEFF2

See all radioligand therapy targets in glioma.

See how PDGFRA ranks against 15,000 targets for your indication.

Analyze PDGFRA free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is PDGFRA the right target for your program? · 5 free analyses, no card Analyze PDGFRA free